Randomized Controlled Trial

NICE has approved nivolumab plus ipilimumab for NHS use in patients with aggressive colorectal cancer, following new evidence of clinical benefit.

Combining oral anticoagulation and antiplatelet therapy post-stroke offers no added protection against recurrence but raises the risk for bleeding, a new meta-analysis finds.

Rilzabrutinib significantly reduces itch and hives in patients with chronic spontaneous urticaria unresponsive to antihistamines, in a phase 2 study.

News, features, and commentary about cancer-related issues

Resubmission of the supplemental biologics license application provided more data on improvement in hives and itching in patients ages 12 and older with CSU.

AXS-12, known as reboxetine back when it was available as an antidepressant in the United States, may decrease cataplexy attacks in narcolepsy, a phase 3 trial suggests.

Randomized trial overturned traditional wisdom on the value of draining pleural fluid.

PROOF-HD analysis suggests potential benefit for those not on anti-dopaminergic meds

Fremanezumab shows safety, efficacy in phase III trial of pediatric patients

Secondary analysis compared chlorthalidone and hydrochlorothiazide

Quetiapine augmentation outperforms lithium augmentation in long-term clinical and cost-effectiveness among adults with treatment-resistant depression, a 52-week trial finds.

As obesity rates rise among individuals with T1D, GLP-1 agonist medications, indicated for T2D and weight loss, are increasingly viewed as adjuncts to insulin.

Maintaining a targeted SpO2 of 90%-96% safely reduces oxygen use but does not significantly increase oxygen-free days in critically-ill patients, a randomized trial shows.

A lack of primary care support, compounded by socioeconomic barriers, can interfere with a family's desire to breastfeed a child.

News and commentary from the world of gastroenterology and hepatology

Treatment shows efficacy in small phase III trial

Inebilizumab, a first-in-class CD19+ B-cell–targeting agent, is safe and effective for up to 1 year in patients with generalized myasthenia gravis, a phase 3 trial suggests.

The noncaloric sweetener sucralose appears to influence how the hypothalamus interprets sweet taste and metabolic signals, potentially influencing appetite regulation over time.

Nearly half of U.S. counties have no cardiologist nearby. A telecardiologist working at the heart of virtual care and cardiology today shows how the technology is helping with this and other challenges.

Many AI products claim to deliver mental health therapy, but with little quality control. But new research suggests with the right training, AI can be effective at helping people.